EIF3I

Across TCGA pan-cancer cohorts, EIF3I mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EIF3I data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF3I mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF3I expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where EIF3I mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.552	0.920	<.001	29	view →
LSCC	DFS	Median	All	0.840	0.579	<.001	27	view →
UCEC	OS	Tertile	II,III,IV	0.648	1.000	.045	8	view →
LUAD	OS	Median	III,IV	0.168	0.787	.014	3	view →
GBM	DFS	Median	All	0.292	0.435	.031	3	view →
PDAC	DFS	Median	III,IV	0.220	0.497	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EIF3I–CCRCC (DFS)

Open the CCRCC breakdown →